Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

The company plans to complete the NDA filing for Xinlay in metastatic prostate cancer by year-end, which is ahead of the timetable predicted after a pivotal trial failed to reach statistical significance. A Phase III trial in a second indication is likely to finish in 2005.